MedTrace Logo

Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure

NCT04385823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2020-05-13

No results posted yet for this study

Summary

Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF. The aim of the study is to describe the use of NHF in Covid-19-related AHRF and report the changes in the respiratory-oxygenation index (termed ROX index) over time in these patients.

Conditions

  • Respiratory Syndrome, Acute, Severe
  • Hypoxic Respiratory Failure
  • Viral Pneumonia

Interventions

DEVICE

patients receiving nasal high flow

patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow

Sponsors & Collaborators

  • Hôpital Louis Mourier

    lead OTHER

Principal Investigators

  • Jean-Damien Ricard, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-05-04
Completion
2020-05-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385823 on ClinicalTrials.gov